(CercleFinance.com) – Jefferies remains long on Moderna shares and maintains its target price of $275.
‘ Investors remain cautious and assume COVID vaccine sales are down, there is no conviction for RSV (respiratory syncytial virus) and influenza, and there are no catalysts ‘, notes the analyst.
Instead, Jefferies thinks the stock should eventually rebound and rise again, but under certain conditions: ‘if the company manages to meet its targets this year; whether competitors and Moderna gain traction in the VRS market; whether new PCV cancer data becomes available in the second half of the year and whether combination vaccines start phase III in the future’.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
